8th Plenary Meeting EHDN 2014 Barcelona: 19-21 settembre 2014 – Report

Annarita Bentivoglio* - Marina Frontali** Si è appena concluso l’ottavo meeting plenario del Network Europeo per la Malattia di Huntington. Oltre 900 partecipanti: l’incontro più numeroso...

Fatal cellular malfunction identified in Huntington’s disease

Researchers believe they have learned how mutations in the gene that causes Huntington’s disease kill brain cells, a finding that could open new opportunities...

CIRM approves $6 million in funding for UCI Researchers to study...

Following a California Institute for Regenerative Medicine (CIRM) Independent Citizens Oversight Committee meeting held last week, University of California, Irvine (UCI) researchers learned they...

ALBORADA Drug Discovery Institute identifies advanced Huntington’s leads using BioAscent’s Compound...

BioAscent’s unique on-demand compound library, Compound Cloud, has been used by the ALBORADA Drug Discovery Institute for virtual screening and to progress promising leads against a novel Huntington’s...

Expert-based clinical guidelines focus on behavioral symptoms in Huntington’s disease

Clinicians treating patients with HD are often not trained to recognize or treat neuropsychiatric symptoms of the disease, according to new guidelines published in...

Huntington’s disease goes viral as UniQure inches ahead in gene therapy...

FDA grants “Investigational New Drug” status to Huntingtin-lowering gene-therapy agent AMT-130, clearing path to human trials in Huntington’s Disease patients Dutch-American company uniQure has received...

First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for...

First of 4+ Ionis programs expected to advance to pivotal studies this yearIonis earns $35 million milestone payment CARLSBAD, Calif., Jan. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:...

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130...

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients...

Study: The Brain’s Support Cells Show Defective Development in Huntington’s Disease

HUNGTINGTON'S DISEASE The neurological disorder Huntington’s disease causes behavioural and motor changes, which among other things are a result of dysfunctional maturation or formation of...

An intellectually active lifestyle protects against neurodegeneration in people with Huntington’s...

The discovery reinforces the importance of leading a cognitively stimulating life to maintain a healthy brain Researchers from the Cognition and Brain Plasticity research group...

Advances on many fronts in the battle against the protein that...

This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager We’ve had a run...

Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral...

One-time delivery of VY-HTT01 for Huntington’s disease achieves significant reduction of HTT gene expression in deeper tissues and outer layers of the brain of...

HDSA FAQ on the Roche/Genentech RG6042 program

HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission) n Wednesday, September 26th, HDSA hosted...

USC scientists map brain region linked to Alzheimer’s and other diseases

Researchers show structures, nerve connections and functions in vivid detail as part of the most detailed atlas yet of a person’s memory bank USC scientists...

Roche announces details of its ‘pivotal’ huntingtin-lowering study

The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease t’s a time of huge developments in the...

New £9.1m contract with a top 10 global pharmaceutical company

Specialist medical imaging services for a Phase III Huntington’s disease clinical trial, highlighting the value of IXICO’s data science expertise in neuroscience drug development. IXICO...

Predict the onset and course of Huntington’s disease

The origin of this incurable nervous disease lies in minute fibers formed by chains of the huntingtin protein MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE IN...

Study Suggests Potential Therapy for Huntington’s Disease

A new study published in the Proceedings of the National Academy of Sciences (PNAS) suggests that Huntington’s disease may take effect much earlier in life than...

PRIME designation granted by European Medicines Agency for RG6042 for treatment...

European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit...

Disappointing news from LEGATO-HD trial of laquinimod in Huntington’s disease

The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown. The LEGATO-HD trial of laquinimod to slow progression of Huntington’s...

HDBuzz Enrolls in Enroll-HD

As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here. The Enroll-HD study...

Malattia di Huntington, un’altra delusione per laquinimod

Un'altra delusione per laquinimod, probabilmente l'ultima. Il farmaco non ha raggiunto l'end point in uno studio di fase II nella malattia di Huntington. Dopo...